6 May 2020 08:56
Oncimmune Holdings plc
Â
("Oncimmune" or the "Company")
Â
PDMR Dealing
Â
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Carsten Schroeder, PDMR and Non-Executive Director, has purchased 18,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for 85 pence per share on 4 May 2020.
Â
Following this transaction, Carsten has a total interest in the Company of 27,000 Ordinary Shares, representing approximately 0.04 per cent of the Company's issued Ordinary Share capital. Â
Â
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Â
1 | Details of the person discharging managerial responsibilities / person closely associated  | ||||
a)  | Name  | Carsten Schroeder | |||
2 Â | Reason for the notification | ||||
a)  | Position/status  | Non-Executive Director | |||
b)  | Initial notification /Amendment  | Initial notification | |||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | ||||
a)  | Name  | Oncimmune Holdings plc | |||
b) Â | LEI | 213800HCYIWT6YPI1I02Â | |||
4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)  | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each  | |||
 |  | ||||
Identification code | ISIN: GB00BYQ94H38 | ||||
 |  | ||||
b)  | Nature of the transaction  | Purchase of shares | |||
c) Â | Price(s) and volume(s) | Â | Â | Â | Â |
 |  | Price | Volume |  | |
 |  | £0.85 | 18,000 |  | |
 |  |  |  |  | |
d) Â | Aggregated information | Â | |||
 |  | ||||
- Aggregated volume | Same as above | ||||
 |  | ||||
- Price | Â | ||||
 |  | ||||
e)  | Date of the transaction  | 4 May 2020 | |||
f) Â | Place of the transaction | London stock exchange, AIM |
Â
For further information:
Â
Oncimmune Holdings plc
Ron Kirschner, General Counsel and Company Secretary
contact@oncimmune.com Â